Table 1 Overview of included studies
Author | Study design/ Level of evidence | Autograft (n, %) | Sex (M/W) (W, %) | Age (Mean ± SD) | Assessment time (Months) |
|---|---|---|---|---|---|
Adachi (2003) [25] | Prospective cohort study Level II | S: 26 (59%) SG: 18 (41%) Total: 44 | S: 15/11 SG: 12/6 Total: 17 (39%) | S: 27.7 ± 10.5 SG: 25.6 ± 8.9 | Both: 12, 35 |
Ardern (2010) [26] | Retrospective cohort study Level III | S: 20 (40%) SG: 30 (60%) Total: 50 | S: 15/5 SG: 20/10 Total: 15 (30%) | S: 27.2 ± 5 SG: 28.7 ± 7 | S: 33.5 ± 4.1 SG: 31.4 ± 7 |
Barenius (2013) [27] | Retrospective cohort study Level III | S: 10 (50%) SG: 10 (50%) Total: 20 | S: 8/2 SG: 8/2 Total: 4 (25%) | S: 26 ± 7 SG: 26 ± 9 | S: 36 ± 4 SG: 37 ± 6 |
Carter (1999) [28] | Randomized controlled trial Level I | S: 33 (49%) SG: 35 (51%) Total: 68 | Â | Â | Both: 6 |
de Geofroy (2022) [29] | Retrospective cohort study Level III | S: 69 (52%) SG: 64 (48%) Total: 133 | S: 66/3 SG: 63/1 Total: 4 (3%) | S: 28.5 ± 6.2 SG: 29.8 ± 6.5 | Both: 4, 8 |
Drocco (2017) [30] | Retrospective cohort study Level III | S: 45 (50%) SG: 45 (50%) Total: 90 | S: 34/11 SG: 27/18 Total: 29 (32%) | S: 29.5 ± 10 SG: 27.7 ± 9 | Both: 6 |
Gillet (2022) [31] | Retrospective cohort study Level III | S: 67 (36%) SG: 119 (64%) Total: 186 | S: 67/0 SG: 119/0 Total: 0 (0%) | S: 26.9 ± 6.4 SG: 25.6 ± 6.1 | Both: 6 |
Inagaki (2013) [32] | Prospective cohort study Level II | S: 61 (51%) SG: 59 (49%) Total: 120 | S: 35/26 SG: 33/26 Total: 52 (43%) | S: 28.2 ± 11.9 SG: 26.2 ± 10.3 | Both: 24 |
Kouloumentas (2019) [33] | Randomized controlled trial Level I | S: 45 (50%) SG: 45 (50%) Total: 90 | S: 28/17 SG: 27/18 Total: 35 (39%) | S: 27.6 ± 11.4 SG: 29.7 ± 11.0 | Both: 24 |
Lee (2019) [34] | Retrospective cohort study Level III | S: 60 (50%) SG: 60 (50%) Total: 120 | S: 57/3 SG: 55/5 Total: 8 (7%) | S: 27.4 ± 6.6 SG: 26.9 ± 7.3 | S: 37.5 ± 5.9 SG: 36.8 ± 6.1 |
Monaco (2018) [35] | Retrospective cohort study Level III | S: 22 (50%) SG: 22 (50%) Total: 44 | S: 15/7 SG: 17/5 Total: 12 (27%) | S: 32.5 ± 6.7 SG: 31.7 ± 7.1 | Both: 13 (12–14) |
Nakamura (2002) [36] | Case–control study Level III | S: 49 (66%) SG: 25 (34%) Total: 74 | S: 28/21 SG: 6/19 Total: 40 (54%) | S: 24.3 SG: 25.7 | Both: 24 |
Roger (2020) [37] | Randomized controlled trial Level I | S: 33 (55%) SG: 27 (45%) Total: 60 | S: 26/7 SG: 23/4 Total: 11 (18%) | S: 30.5 ± 8.9 SG: 30.3 ± 8.5 | Both: 6, 24 |
Sengoku (2022) [38] | Retrospective cohort study Level III | S: 41 (50%) SG: 41 (50%) Total: 82 | S: 21/20 SG: 21/20 Total: 40 (49%) | S: 21.7 ± 9.2 SG: 19.6 ± 7 | Both: 3, 6 |
Yosmaoglu (2011) [39] | Prospective cohort study Level II | S: 23 (50%) SG: 23 (50%) Total: 46 | S: 23/0 SG: 23/0 Total: 0 (0%) | S: 29 ± 7 SG: 28 ± 9 | Both: 12 |